Understanding Glaucoma and Cannabinoids: What You Need to Know

Glaucoma is a serious condition that affects intraocular pressure and can lead to vision loss. Our eye doctors help unravel the complex relationship between glaucoma treatment and cannabinoids.

Table of Contents

Introduction
Marijuana’s Impact on Intraocular Pressure and Glaucoma
How Cannabinoids Work in the Eye
Routes of Administration and Their Efficacy
Short Duration of Action and Practical Limitations
Understanding Glaucoma and Cannabinoids: What You Need to Know
Understanding Glaucoma and Cannabinoids: What You Need to Know
Find a Glaucoma Treatment eye doctor near me

Introduction

Glaucoma is a serious eye condition characterized by increased intraocular pressure (IOP) that can damage the optic nerve and lead to vision loss if not managed properly. Marijuana has been discussed as a potential way to lower IOP and protect retinal cells, but its use in treating glaucoma remains controversial. Our eye doctors are here to explain the science behind marijuana’s effects on glaucoma and help you understand why current treatments are often preferred.

Marijuana’s Impact on Intraocular Pressure and Glaucoma

Understanding glaucoma starts with appreciating the role of IOP and the flow of aqueous humor in the eye. The aqueous humor is a clear fluid produced by the ciliary body that circulates through the trabecular meshwork and Schlemm’s canal, maintaining eye integrity and pressure. When there is an imbalance between fluid production and clearance, IOP increases, and that elevated pressure can harm the optic nerve over time.

Marijuana contains cannabinoids—compounds such as Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)—that interact with our body’s endocannabinoid system (ECS). These cannabinoids bind to receptors prominently found in the ciliary body, trabecular meshwork, and Schlemm’s canal, which are all critical to regulating aqueous humor outflow and consequently lowering IOP. While THC has been shown in some studies to reduce IOP significantly, CBD has not demonstrated the same efficacy and may even have an opposing effect.

How Cannabinoids Work in the Eye

Here’s the science behind it: cannabinoids engage with the ECS, which is present throughout the body and the eye. Two key endocannabinoids naturally found in our system—2-arachidonoyl glycerol and anandamide—help regulate ocular functions by binding to CB1 receptors in the eye. When exogenous cannabinoids like THC are introduced, they mimic these natural processes by:

Inducing contraction of the ciliary body, which helps reduce the production of aqueous humor.
Widening the drainage channels such as Schlemm’s canal to promote fluid outflow.
Enhancing the function of the trabecular meshwork, thus facilitating a smoother clearance process.

These actions collectively contribute to a lowering of IOP. However, it’s important to note that despite these promising mechanisms, the duration of marijuana’s IOP-lowering effects is typically very short—lasting just three to four hours—which poses a significant challenge for long-term glaucoma management.

If you have questions about glaucoma or want to find a top optometrist near you, contact our office today!

Routes of Administration and Their Efficacy

Marijuana can be consumed via different methods, each with its pros and cons when it comes to managing glaucoma. Smoking marijuana has been the traditional method studied and has been shown to lower IOP effectively. However, the short duration of action means that a patient would need to smoke frequently—around six to eight times a day—to maintain consistent IOP control.

Other routes include:

Sublingual and Intravenous Administration: Studies show that these methods can reduce IOP, though the effect is still transient. Sublingual application, in particular, has demonstrated a temporary drop in pressure, but consistent levels are hard to achieve.
Topical Application: Eye drops containing cannabinoids are appealing because they target the eye directly with fewer systemic side effects. Unfortunately, due to the low aqueous solubility of cannabinoids and rapid drug clearance via lacrimation, topical formulations have not consistently demonstrated effective IOP reduction.
Oral Intake: While ingesting cannabinoids shows some promise, their absorption rates are unpredictable. This variability makes it difficult to maintain a stable concentration in the bloodstream and consequently in the eye.

Thus, while several methods have been explored, none have provided a practical solution for managing glaucoma on a 24-hour basis.

Short Duration of Action and Practical Limitations

One of the main challenges with marijuana as a treatment for glaucoma is its short duration of IOP-lowering effect. Research has consistently shown that although initial reductions in IOP can be achieved, these effects generally dissipate within a few hours. This means that to sustain lower IOP levels, frequent dosing would be required throughout the day.

This poses several problems:

Frequent dosing leads to the potential for drug tolerance, where the eye becomes less responsive over time, reducing the drug’s effectiveness.
The psychoactive effects of frequent THC exposure—such as altered mood, reduced mental clarity, and impaired coordination—can interfere with daily activities like driving or operating machinery.
There is also the possibility of abuse or non-compliance, as patients might use the medication based on neurogenic cravings rather than following a fixed schedule.

These limitations have led professional organizations, including the American Academy of Ophthalmology and the American Glaucoma Society, to advise against using marijuana as a primary treatment for glaucoma.